Oncology – Gastrointestinal
RCT | Zolbetuximab plus CAPOX as potential first-line treatment for CLDN18.2+, HER2- advanced gastric adenocarcinoma
7 Aug, 2023 | 14:38h | UTC
Commentary on Twitter
In the phase 3 GLOW trial, CAPOX plus zolbetuximab significantly improved progression free survival and overall survival in patients with CLDN18.2+, HER2- untreated #GastricCancer or gastroesophageal junction adenocarcinoma @AstellasUS @mdmanishshah https://t.co/YYbLHhiyOq
— Nature Medicine (@NatureMedicine) August 1, 2023
ACP Guidance | Asymptomatic CRC screening advised from age 50 with fecal occult blood test every 2 years or colonoscopy every 10 years
3 Aug, 2023 | 13:48h | UTCNews Release: ACP issues updated guidance for colorectal cancer screening of asymptomatic adults – American College of Physicians
Commentary: Start screening for colorectal cancer at age 50 years, ACP suggests – ACP Internist
Summary for Patients: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults – Annals of Internal Medicine
RCT | Camrelizumab-rivoceranib outperforms sorafenib as first-line therapy for unresectable HCC
2 Aug, 2023 | 13:53h | UTCCamrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
New @TheLancet – Qin et al – Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 studyhttps://t.co/YoutfY5IkA#LiverTwitter #OncTwitter #LiverCancer #HCC pic.twitter.com/Tcvm6D3kCW
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) July 25, 2023
Nonrandomized Controlled Trial | Long-term survival of 80% in selected colorectal cancer patients post liver transplant
1 Aug, 2023 | 14:20h | UTCLong-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant: A Nonrandomized Controlled Trial – JAMA Surgery (link to abstract – $ for full-text)
Commentary on Twitter
Selected patients with liver-only CRLM and favorable pre-transplant prognostic scoring have long-term OS comparable to conventional indications for LT, providing a potential curative treatment option in patients otherwise offered only palliative treatments https://t.co/Xso5R7IDsX pic.twitter.com/uwEWijcrBp
— JAMA Surgery (@JAMASurgery) July 26, 2023
RCT | Efficacy of different treatment regimens in unresectable colorectal cancer liver metastases
14 Jul, 2023 | 12:42h | UTCFirst-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
ICYMI: The CAIRO5 open-label, multicentre, randomised, phase 3 trial of first-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases. #ccsmhttps://t.co/PiiwFcktLn pic.twitter.com/wlQbmuDLOW
— The Lancet Oncology (@TheLancetOncol) July 5, 2023
RCT | FOLFOXIRI-Bevacizumab shows promise as first-line treatment in unresectable colorectal cancer metastases
5 Jul, 2023 | 01:02h | UTCFirst-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group – The Lancet Oncology (link to abstract – $ for full-tetxt)
Consensus Paper | Colorectal neuroendocrine tumors
30 Jun, 2023 | 14:45h | UTC
SR | Supportive care interventions for managing gastrointestinal symptoms following treatment for colorectal cancer
22 Jun, 2023 | 14:49h | UTC
RCT | Fruquintinib extends median survival to 7.4 months vs. 4.8 months with placebo in refractory metastatic colorectal cancer
19 Jun, 2023 | 14:02h | UTCFruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter questioning the control group (thread – click for more)
Disgusting, unethical PLACEBO control trial in colon cancer just so Fruquitinib can win
I will show you that placebo should not have been the control arm, & the IRBs & FDA failed 🧵
First, this trial tests a new drug vs. placebo (sugar pill) in patients dying of colon cancer pic.twitter.com/fa915vgUbp
— Vinay Prasad MD MPH (@VPrasadMDMPH) June 17, 2023
Cohort Study | Overweight or obesity in early and middle adulthood linked to higher gastrointestinal cancer risk
5 Jun, 2023 | 13:34h | UTCEditorial: Obesity and Gastrointestinal Cancer: A Life Course Perspective – JAMA Network Open
Commentary: Association Between Overweight/Obesity and Risk of Gastrointestinal Cancer – The ASCO Post
AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
30 May, 2023 | 11:51h | UTC
M-A | Prehabilitation may enhance functional capacity in pre- and postoperative colorectal cancer patients
30 May, 2023 | 11:50h | UTCSummary: Preparing a patient with bowel cancer for surgery with multiple interventions – Cochrane Library
Review | Cholangiocarcinoma — novel biological insights and therapeutic strategies
22 May, 2023 | 13:38h | UTC
Commentary on Twitter
In a new Review, Greg Gores & co. discuss advances in cholangiocarcinoma over the past 5 yrs, focusing on the immune TME, CAFs, molecular diagnostics & classifications, target therapy, immunotherapy & transplantation:https://t.co/f4BYxY69tk #hpbcsm #medonc #camoldx #camicroenv pic.twitter.com/lqmwgp9hxh
— NatureRevClinOncol (@NatRevClinOncol) May 16, 2023
Review | Hereditary colorectal, gastric, and pancreatic cancer
18 May, 2023 | 13:43h | UTCHereditary colorectal, gastric, and pancreatic cancer: comprehensive review – BJS Open
Commentary on Twitter
Have a🔎at our latest comprehensive review covering all u need to know📜about hereditary 🧬colorectal, gastric & pancreatic🦀! https://t.co/y1LL0DNRiy@Adductor @DrRABurkhart #SoMe4Surgery #StepUp4CRC #SurgEd #MedTwitter @BJSAcademy @BJSurgery @juliomayol @young_bjs Great read! pic.twitter.com/JmmOmMBydO
— BJS Open (@BjsOpen) May 11, 2023
Current perioperative care in pancreatoduodenectomy: a step-by-step surgical roadmap from first visit to discharge
16 May, 2023 | 14:52h | UTC
Commentary on Twitter
Step by step surgical roadmap 🗺️ for pancreatoduodenectomy
🧭 Pre, intra and post operative periods have specific landmarks
⚖️ Such factors weight the actual value of surgery vs. alternative options
🔑 is minimize complications and patients selectionhttps://t.co/3obsQdfHs6 pic.twitter.com/6EHoRjc2wE
— Giovanni Marchegiani (@Gio_Marchegiani) April 27, 2023
An update on the role of immunohistochemistry in the evaluation of pancreatic/liver/gastrointestinal luminal tract disorders
15 May, 2023 | 13:02h | UTC
2023 Rectal cancer lexicon update | Revised consensus on terminology and staging
15 May, 2023 | 12:50h | UTC
EASL-ILCA Clinical practice guidelines on the management of intrahepatic cholangiocarcinoma
9 May, 2023 | 14:47h | UTC
Commentary on Twitter
🆕#CPG in press❕
EASL-ILCA Clinical Practice Guidelines on the management of #IntrahepaticCholangiocarcinoma
🆓Find it here👉https://t.co/buM8rgBU1F@EASLedu@EASLnews#iCCA#LiverTwitter pic.twitter.com/raR983x0qk
— Journal of Hepatology (@JHepatology) April 20, 2023
RCT | Tislelizumab plus chemotherapy vs placebo plus chemotherapy for advanced esophageal squamous cell carcinoma
8 May, 2023 | 13:04h | UTCTislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NOW OF: Interim analysis of the RATIONALE-306 trial of 1st-line tislelizumab + chemo vs placebo + chemo in adv or metastatic oesophageal squamous cell carcinoma—median OS 17·2 mo (95% CI 15·8–20·1) vs 10·6 mo (9·3–12·1; HR 0·66, 95% CI 0·54–0·80; p<0·0001)https://t.co/25lyg2Ef0o pic.twitter.com/vizCPVd8bj
— The Lancet Oncology (@TheLancetOncol) April 18, 2023
RCT | Adding Bevacizumab to trifluridine–tipiracil enhances overall survival in refractory metastatic colorectal cancer
5 May, 2023 | 15:13h | UTCTrifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among patients with metastatic colorectal cancer, treatment with trifluridine–tipiracil plus bevacizumab as third-line therapy resulted in longer overall survival than trifluridine–tipiracil alone (SUNLIGHT trial). https://t.co/C4DZvyiZiD pic.twitter.com/gHTR9jbJS5
— NEJM (@NEJM) May 3, 2023
RCT | Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer
2 May, 2023 | 13:36h | UTCEfficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Invited Commentary: Heated Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer–Restarting the Fire – JAMA Surgery (free for a limited period)
Commentary on Twitter
Hyperthermic intraperitoneal chemotherapy with mitomycin C along with complete cytoreduction improved locoregional control in patients with locally advanced colorectal cancer and should be considered for treatment of locally advanced colorectal cancer. https://t.co/hOM4TvgILB
— JAMA Surgery (@JAMASurgery) April 26, 2023
Review | Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma
28 Apr, 2023 | 13:03h | UTC
M-A | Immune checkpoint inhibitors vs. chemotherapy in the 2nd-line treatment of advanced esophageal squamous cell carcinoma
28 Apr, 2023 | 12:56h | UTC
RCT | Intraperitoneal carboplatin achieves modest PFS gains in advanced ovarian cancer
25 Apr, 2023 | 14:24h | UTCIntraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial – NEJM Evidence
Commentary on Twitter
“In the first-line treatment of advanced epithelial ovarian cancer, intraperitoneal carboplatin resulted in a modest prolongation of PFS [progression-free survival] when given with dose-dense weekly paclitaxel regardless of residual tumor size….”#MedTwitter #ClinicalTrials
— NEJM Evidence (@NEJMEvidence) April 23, 2023
RCT | Panitumumab vs. Bevacizumab added to 1st-line chemo in RAS wild-type left-sided metastatic colorectal cancer
24 Apr, 2023 | 13:41h | UTCPanitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift – JAMA Oncology (free for a limited period)
Commentary on Twitter
Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, vs bevacizumab, to standard first-line chemotherapy significantly improved overall survival in patients with left-sided tumors and in the overall population. https://t.co/Hjh9f3fN1z #AACR23 pic.twitter.com/uZxQUkfNbB
— JAMA (@JAMA_current) April 18, 2023